SLCO2A1

Summary

SLCO2A1 (solute carrier organic anion transporter family member 2A1, HGNC:10955) is a protein-coding gene on chromosome 3q22.1-q22.2, encoding Solute carrier organic anion transporter family member 2A1 (Q92959). Mediates the transport of prostaglandins (PGs, mainly PGE2, PGE1, PGE3, PGF2alpha, PGD2, PGH2) and thromboxanes (thromboxane B2) across the cell membrane.

This gene encodes a prostaglandin transporter that is a member of the 12-membrane-spanning superfamily of transporters. The encoded protein may be involved in mediating the uptake and clearance of prostaglandins in numerous tissues.

Source: NCBI Gene 6578 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hypertrophic osteoarthropathy, primary, autosomal dominant (Definitive, GenCC) — +4 more curated relationships
• GWAS associations: 3
• Clinical variants (ClinVar): 363 total — 37 pathogenic, 21 likely-pathogenic
• Phenotypes (HPO): 54
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005630

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10955
Approved symbol	SLCO2A1
Name	solute carrier organic anion transporter family member 2A1
Location	3q22.1-q22.2
Locus type	gene with protein product
Status	Approved
Aliases	PGT, OATP2A1
Ensembl gene	ENSG00000174640
Ensembl biotype	protein_coding
OMIM	601460
Entrez	6578

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 11 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000310926, ENST00000462770, ENST00000464676, ENST00000477061, ENST00000478651, ENST00000478662, ENST00000481359, ENST00000493729, ENST00000860067, ENST00000860068, ENST00000860069, ENST00000860070, ENST00000860071, ENST00000860072, ENST00000860073, ENST00000860074, ENST00000860075

RefSeq mRNA: 1 — MANE Select: NM_005630 NM_005630

CCDS: CCDS3084

Canonical transcript exons

ENST00000310926 — 14 exons

Exon	Start	End
ENSE00001184806	133948893	133948971
ENSE00001184828	133932701	133934830
ENSE00001250528	134029707	134029925
ENSE00001305936	133951208	133951344
ENSE00003531773	133979481	133979618
ENSE00003541500	133945095	133945260
ENSE00003581552	133947256	133947445
ENSE00003599910	133973663	133973825
ENSE00003601676	133953663	133953761
ENSE00003617669	133954966	133955193
ENSE00003618950	133935774	133935897
ENSE00003622918	133948536	133948700
ENSE00003644863	133942605	133942768
ENSE00003657886	133938429	133938493

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 99.40.

FANTOM5 (CAGE): breadth broad, TPM avg 6.1463 / max 585.1530, expressed in 641 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
44681	5.0564	561
44682	0.6154	267
44683	0.2787	135
44684	0.1410	70
44677	0.0549	23

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lung	UBERON:0002167	99.40	gold quality
upper lobe of left lung	UBERON:0008952	97.97	gold quality
upper lobe of lung	UBERON:0008948	97.87	gold quality
right lobe of thyroid gland	UBERON:0001119	97.77	gold quality
left lobe of thyroid gland	UBERON:0001120	97.35	gold quality
thyroid gland	UBERON:0002046	96.91	gold quality
lower lobe of lung	UBERON:0008949	96.53	gold quality
seminal vesicle	UBERON:0000998	96.33	gold quality
lung	UBERON:0002048	94.85	gold quality
cardia of stomach	UBERON:0001162	94.10	gold quality
left uterine tube	UBERON:0001303	94.04	gold quality
mucosa of stomach	UBERON:0001199	93.42	gold quality
body of uterus	UBERON:0009853	93.28	gold quality
left adrenal gland cortex	UBERON:0035825	93.26	gold quality
adrenal cortex	UBERON:0001235	93.19	gold quality
left adrenal gland	UBERON:0001234	93.11	gold quality
decidua	UBERON:0002450	92.84	gold quality
tendon of biceps brachii	UBERON:0008188	92.73	gold quality
right adrenal gland	UBERON:0001233	92.55	gold quality
myometrium	UBERON:0001296	92.55	gold quality
right adrenal gland cortex	UBERON:0035827	92.46	gold quality
ectocervix	UBERON:0012249	91.96	gold quality
smooth muscle tissue	UBERON:0001135	91.81	gold quality
adrenal gland	UBERON:0002369	91.50	gold quality
right coronary artery	UBERON:0001625	91.07	gold quality
pylorus	UBERON:0001166	90.71	gold quality
left coronary artery	UBERON:0001626	90.47	gold quality
fundus of stomach	UBERON:0001160	90.34	gold quality
palpebral conjunctiva	UBERON:0001812	90.33	gold quality
gall bladder	UBERON:0002110	90.23	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-ANND-2	yes	713.61
E-GEOD-135922	yes	636.52
E-HCAD-11	yes	42.76
E-CURD-119	yes	40.43
E-HCAD-1	yes	39.28
E-MTAB-8410	yes	22.10
E-MTAB-6678	yes	6.33
E-MTAB-10137	no	515.82
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

88 targeting SLCO2A1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-5093	99.67	69.26	2291

Literature-anchored findings (GeneRIF, showing 40)

• Human endometrial stromal cells treated with a combination of cAMP and medroxyprogesterone acetate to induce decidualization showed an increase in protein and mRNA levels. (PMID:16339169)
• PGT level was significantly less in AD than in age-matched control brain homogenates. (PMID:18353443)
• The existing model to explain increased PGE(2) in colorectal neoplasia should be modified to include the novel mechanism of coordinated up- and down-regulation of genes involved in PGE(2) transport. (PMID:19138942)
• that PGT may play a role in transporting PGH(2) across cellular membranes. (PMID:20346915)
• expression in fetal membranesfound primarily in the choriodecidua (PMID:20357271)
• we found no indication for an association between SNPs in the prostaglandin F(2alpha) receptor gene or SLCO2A1 and IOP response to prostaglandin analogs in a population of European descent. (PMID:22060278)
• The findings confirmed that SLCO2A1 mutations inactivate prostaglandin E2 transport, and they indicated that mutations in SLCO2A1 are the pathogenic cause of primary hypertrophic osteoarthropathy. (PMID:22197487)
• Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. (PMID:22331663)
• Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. (PMID:22553128)
• Mutations in the prostaglandin transporter SLCO2A1 cause primary hypertrophic osteoarthropathy with digital clubbing. (PMID:22696055)
• Report SLCO2A1 is a novel gene responsible for pachydermoperiostosis in Japanese patients. (PMID:22906430)
• genetic association study in population in China: Nine different SLCO2A1 mutations were identified in subjects with primary hypertrophic osteoarthropathy (PHO) in 7 previously undescribed families; different homozygous mutations of SLCO2A1 cause PHO. (PMID:23509104)
• Three novel mutations within the SLCO2A1 gene have been demonstrated to be associated with Chinese primary hypertrophic osteoarthropathy patients. (PMID:24153155)
• Identified two novel mutations in SLCO2A1. (PMID:24185079)
• Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development. (PMID:24694755)
• SLCO2A1 has a role in familial digital clubbing, colon neoplasia, and NSAID resistance (PMID:24838973)
• a novel nonsense mutation p.E141* of the SLCO2A1 gene is associated with pachydermoperiostosis (PMID:24929850)
• In this article we describe a novel mutation in the SLCO2A1 causing Pachydermoperiostosis in a Lebanese family (PMID:25059581)
• OATP2A1 also diminished the PGE2-mediated expression of interleukin-8 mRNA (IL-8) and hypoxia-inducible-factor 1alpha (HIF1alpha) protein in AGS-OATP2A1 cells. (PMID:25433165)
• Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. (PMID:25433169)
• We herein report patients with pachydermoperiostosis (PDP)due to SLCO2A1 mutation in a Korean family. Similar to other East Asian populations, the SLCO2A1 gene may be a possible mutation spot of PDP in the Korean population. (PMID:25810087)
• SLCO2A1 and NOS3 are involved with prostaglandin reuptake/metabolism and nitric oxide production, respectively, and are consistently decreased in “non-Caucasian” fetal ductus arteriosus (PMID:26265282)
• overexpression of SLCO2A1 could induce and knockdown inhibit the invasion of lung cancer cells. expression levels of p-mTOR, p-AKT and p-S6 were up-regulated or down-regulated with the overexpression or knockdown of SLCO2A1. (PMID:26464663)
• findings indicate that loss-of-function mutations in the SLCO2A1 gene encoding a prostaglandin transporter cause the hereditary enteropathy CNSU (PMID:26539716)
• Data show that prostaglandin E3 (PGE3) uptake by prostaglandin transporter OATP2A1-expressing HEK293 cells (HEK/2A1) was the highest and followed by SLCO2B1 (HEK/1B1). (PMID:26692285)
• cytoplasmic OATP2A1 likely facilitates prostaglandin E2 loading into suitable intracellular compartment(s) for efficient exocytotic prostaglandin E2 release from colorectal cancer cells exposed to oxidative stress (PMID:26850138)
• Mutation analysis revealed a novel heterozygous mutation in the solute carrier organic anion transporter family member 2A1 gene at nucleotide 302 causing a substitution of the amino acid isoleucine to serine at codon 101 (p.IIe101Ser) in affected individuals. (PMID:27134495)
• An association was found between single nucleotide polymorphisms of the PTGFR and SLCO2A1 genes and the response to latanoprost in Han Chinese patients with glaucoma. These SNPs may be important determinants of differential response to latanoprost. (PMID:27336732)
• In Japanese patients with chronic nonspecific multiple ulcers of the small intestine, 2 of the 4 patients had mutation in the SLCO2A1 gene, became resistant to medical therapy, and underwent strictureplasty or ileal resection after long-term follow-up. (PMID:27467110)
• The findings reported here support causality of this SLCO2A1 mutation for autosomal recessive ICNC in this consanguineous Pakistani kindred. (PMID:27681482)
• A novel missense mutation c.101T > C in the SLCO2A1 gene causes pachydermoperiostosis of the complete type. (PMID:28602931)
• in individuals carrying the SLCO2A1 A396T variant, the combination of thiazide-specific effects on free water generation and the increase in collecting duct water permeability from reduced SLCO2A1 activity combine to produce thiazide-induced hyponatremia (PMID:28783044)
• The expression of SLCO2A1 was observed in one of four patients with chronic enteropathy associated with SLCO2A1 (CEAS) and in all 29 patients with Crohn’s Disease. The three with CEAS without SLCO2A1 expression had a homozygous splice-site mutation in SLCO2A1. The remaining one CEAS patient with positive expression of SLCO2A1 had compound heterozygous mutations. (PMID:30400730)
• A novel SLCO2A1 compound heterozygous mutation of p.I284V and p.C459R was identified in two PHO patients in a chinese family. (PMID:31004291)
• Chronic enteropathy associated with SLCO2A1 gene: A case report and literature review. (PMID:31196708)
• A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy. (PMID:33166338)
• [Clinical and genetic characteristics of patients with chronic enteropathy associated with SLCO2A1 gene]. (PMID:33397021)
• Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans. (PMID:33619025)
• Phenolsulfonphthalein as a surrogate substrate to assess altered function of the prostaglandin transporter SLCO2A1. (PMID:35299026)
• Clinical and Genetic Characteristics of Korean Patients Diagnosed with Chronic Enteropathy Associated with SLCO2A1 Gene: A KASID Multicenter Study. (PMID:35611666)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	slco2a1	ENSDARG00000061896
mus_musculus	Slco2a1	ENSMUSG00000032548
rattus_norvegicus	Slco2a1	ENSRNOG00000009005
drosophila_melanogaster	Oatp30B	FBGN0032123

Paralogs (10): SLCO1A2 (ENSG00000084453), SLCO4A1 (ENSG00000101187), SLCO1B3 (ENSG00000111700), SLCO1B1 (ENSG00000134538), SLCO2B1 (ENSG00000137491), SLCO5A1 (ENSG00000137571), SLCO1C1 (ENSG00000139155), SLCO4C1 (ENSG00000173930), SLCO3A1 (ENSG00000176463), SLCO6A1 (ENSG00000205359)

Protein

Protein identifiers

Solute carrier organic anion transporter family member 2A1 — Q92959 (reviewed: Q92959)

Alternative names: OATP2A1, PHOAR2, Prostaglandin transporter, Solute carrier family 21 member 2

All UniProt accessions (3): E7EU40, Q92959, F8W9W8

UniProt curated annotations — full annotation on UniProt →

Function. Mediates the transport of prostaglandins (PGs, mainly PGE2, PGE1, PGE3, PGF2alpha, PGD2, PGH2) and thromboxanes (thromboxane B2) across the cell membrane. PGs and thromboxanes play fundamental roles in diverse functions such as intraocular pressure, gastric acid secretion, renal salt and water transport, vascular tone, and fever. Plays a role in the clearance of PGs from the circulation through cellular uptake, which allows cytoplasmic oxidation and PG signal termination. PG uptake is dependent upon membrane potential and involves exchange of a monovalent anionic substrate (PGs exist physiologically as an anionic monovalent form) with a stoichiometry of 1:1 for divalent anions or of 1:2 for monovalent anions. Uses lactate, generated by glycolysis, as a counter-substrate to mediate PGE2 influx and efflux. Under nonglycolytic conditions, metabolites other than lactate might serve as counter-substrates. Although the mechanism is not clear, this transporter can function in bidirectional mode. When apically expressed in epithelial cells, it facilitates transcellular transport (also called vectorial release), extracting PG from the apical medium and facilitating transport across the cell toward the basolateral side, whereupon the PG exits the cell by simple diffusion. In the renal collecting duct, regulates renal Na+ balance by removing PGE2 from apical medium (PGE2 EP4 receptor is likely localized to the luminal/apical membrane and stimulates Na+ resorption) and transporting it toward the basolateral membrane (where PGE2 EP1 and EP3 receptors inhibit Na+ resorption). Plays a role in endometrium during decidualization, increasing uptake of PGs by decidual cells. Involved in critical events for ovulation. Regulates extracellular PGE2 concentration for follicular development in the ovaries. Expressed intracellularly, may contribute to vesicular uptake of newly synthesized intracellular PGs, thereby facilitating exocytotic secretion of PGs without being metabolized. Essential core component of the major type of large-conductance anion channel, Maxi-Cl, which plays essential roles in inorganic anion transport, cell volume regulation and release of ATP and glutamate not only in physiological processes but also in pathological processes. May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier.

Subcellular location. Cell membrane. Basal cell membrane. Cytoplasm. Lysosome.

Tissue specificity. Ubiquitous. Significant expression observed in lung, kidney, spleen, and heart. Expressed in the endometrium (at both mRNA and protein levels). Expressed in the ovaries (at mRNA and protein levels). In testis, primarily localized to the basal membrane of Sertoli cells and weakly expressed within the tubules.

Disease relevance. PHOAR2-enteropathy syndrome (PHOAR2E) [MIM:614441] An autosomal recessive disease characterized by primary hypertrophic osteoarthropathy and/or chronic non-specific ulcers of the small intestine. Affected individuals present with digital clubbing, periostosis, acroosteolysis, painful joint enlargement, and variable features of pachydermia that include thickened facial skin and a thickened scalp. Chronic ulcers of the small intestine result in abdominal pain and watery diarrhea, and are associated with chronic anemia. Other developmental anomalies include delayed closure of the cranial sutures and congenital heart disease. The disease is caused by variants affecting the gene represented in this entry. Hypertrophic osteoarthropathy, primary, autosomal dominant (PHOAD) [MIM:167100] A form of primary hypertrophic osteoarthropathy, a disease characterized by digital clubbing, periostosis, acroosteolysis, painful joint enlargement, and variable features of pachydermia that include thickened facial skin and a thickened scalp. PHOAD patients may also experience joint swelling and pain, and some have reported gastrointestinal symptoms, including watery diarrhea. Males are more commonly affected, and more severely affected, than females. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Chorionic gonadotropin stimulates expression in the ovaries.

Similarity. Belongs to the organo anion transporter (TC 2.A.60) family.

RefSeq proteins (1): NP_005621* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002350	Kazal_dom	Domain
IPR004156	OATP	Family
IPR020846	MFS_dom	Domain
IPR036058	Kazal_dom_sf	Homologous_superfamily
IPR036259	MFS_trans_sf	Homologous_superfamily

Pfam: PF03137, PF07648

Catalyzed reactions (Rhea), 8 shown:

• prostaglandin E2(out) = prostaglandin E2(in) (RHEA:50984)
• prostaglandin E3(out) + 2 (S)-lactate(in) = prostaglandin E3(in) + 2 (S)-lactate(out) (RHEA:74351)
• prostaglandin H2(out) + 2 (S)-lactate(in) = prostaglandin H2(in) + 2 (S)-lactate(out) (RHEA:74379)
• prostaglandin E2(out) + 2 (S)-lactate(in) = prostaglandin E2(in) + 2 (S)-lactate(out) (RHEA:74383)
• prostaglandin E1(out) + 2 (S)-lactate(in) = prostaglandin E1(in) + 2 (S)-lactate(out) (RHEA:74395)
• prostaglandin F2alpha(out) + 2 (S)-lactate(in) = prostaglandin F2alpha(in) + 2 (S)-lactate(out) (RHEA:74399)
• prostaglandin D2(out) + 2 (S)-lactate(in) = prostaglandin D2(in) + 2 (S)-lactate(out) (RHEA:74403)
• thromboxane B2(out) + 2 (S)-lactate(in) = thromboxane B2(in) + 2 (S)-lactate(out) (RHEA:74407)

UniProt features (113 total): helix 30, sequence variant 24, strand 14, topological domain 13, transmembrane region 12, turn 10, glycosylation site 3, disulfide bond 3, sequence conflict 2, chain 1, domain 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
3MRR	X-RAY DIFFRACTION	1.6
8KGW	ELECTRON MICROSCOPY	2.96
9JV1	ELECTRON MICROSCOPY	3.1
8KGI	ELECTRON MICROSCOPY	3.2
8KGV	ELECTRON MICROSCOPY	3.2
9JUQ	ELECTRON MICROSCOPY	3.2
9MGK	ELECTRON MICROSCOPY	4.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92959-F1	82.27	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 444–474, 450–470, 459–494

Glycosylation sites (3): 134, 478, 491

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-5619095	Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)
R-HSA-879518	Organic anion transport by SLCO transporters
R-HSA-1643685	Disease
R-HSA-382551	Transport of small molecules
R-HSA-425397	Transport of vitamins, nucleosides, and related molecules
R-HSA-425407	SLC-mediated transmembrane transport
R-HSA-5619102	SLC transporter disorders
R-HSA-5619115	Disorders of transmembrane transporters

MSigDB gene sets: 294 (showing top): GSE45365_NK_CELL_VS_BCELL_UP, GOBP_SODIUM_INDEPENDENT_ORGANIC_ANION_TRANSPORT, BENPORATH_ES_WITH_H3K27ME3, TGACCTY_ERR1_Q2, SAENZ_DETOX_PATHWAY_AND_CARCINOGENESIS_DN, GOBP_ORGANIC_ACID_TRANSPORT, BROWNE_HCMV_INFECTION_48HR_DN, HOSHIDA_LIVER_CANCER_SUBCLASS_S3, ROZANOV_MMP14_TARGETS_UP, NF1_Q6_01, KYNG_DNA_DAMAGE_BY_GAMMA_RADIATION, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, GOBP_ORGANIC_ANION_TRANSPORT, MORF_EPHA7, GOBP_MONOCARBOXYLIC_ACID_TRANSPORT

GO Biological Process (5): lipid transport (GO:0006869), prostaglandin transport (GO:0015732), sodium-independent organic anion transport (GO:0043252), monoatomic ion transport (GO:0006811), transmembrane transport (GO:0055085)

GO Molecular Function (5): lipid carrier activity (GO:0005319), prostaglandin transmembrane transporter activity (GO:0015132), obsolete sodium-independent organic anion transmembrane transporter activity (GO:0015347), protein binding (GO:0005515), transmembrane transporter activity (GO:0022857)

GO Cellular Component (6): lysosome (GO:0005764), plasma membrane (GO:0005886), basal plasma membrane (GO:0009925), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
SLC transporter disorders	1
SLC-mediated transport of organic anions	1
SLC-mediated transmembrane transport	1
Transport of small molecules	1
Disorders of transmembrane transporters	1
Disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	3
transmembrane transport	2
plasma membrane region	2
cellular anatomical structure	2
lipid localization	1
fatty acid transport	1
icosanoid transport	1
cellular process	1
molecular carrier activity	1
prostaglandin transport	1
icosanoid transmembrane transporter activity	1
binding	1
transporter activity	1
lytic vacuole	1
membrane	1
cell periphery	1
basal part of cell	1
basal plasma membrane	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1114 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLCO2A1	ITIH4	Q14624	877
SLCO2A1	HPGD	P15428	766
SLCO2A1	ABCC4	O15439	596
SLCO2A1	MAN1A1	P33908	591
SLCO2A1	AMH	P03971	588
SLCO2A1	PTGFR	P43088	543
SLCO2A1	PTGER2	P43116	537
SLCO2A1	PTGER4	P35408	526
SLCO2A1	PTGES	O14684	512
SLCO2A1	PTGER3	P43115	454
SLCO2A1	PPARG	P37231	451
SLCO2A1	ABCB1	P08183	449
SLCO2A1	GNRH1	P01148	447
SLCO2A1	NR1I2	O75469	435
SLCO2A1	SLC22A8	Q8TCC7	429

IntAct

3 interactions, top by confidence:

A	B	Type	Score
SLCO2A1	GRB2	psi-mi:“MI:0915”(physical association)	0.400
SLCO2A1	ATP5PD	psi-mi:“MI:0914”(association)	0.350

BioGRID (6): ACBD3 (Affinity Capture-MS), ATP5D (Affinity Capture-MS), ATP5H (Affinity Capture-MS), PLD3 (Affinity Capture-MS), RDH14 (Affinity Capture-MS), TMX1 (Affinity Capture-MS)

ESM2 similar proteins: A1L1W9, A1L272, A2SWM2, A8WGF7, D3Z5L6, D4A9K4, F4IKF6, G5E8K6, G8XYX6, O15374, O35440, O70324, O70451, O70594, P30638, P36021, P53985, P53986, P53987, P53988, P57057, P58355, Q00910, Q03064, Q0VA82, Q3MHW6, Q3U9N9, Q569T7, Q5M7K3, Q5U3U7, Q5XGK0, Q63344, Q640L2, Q6DCX5, Q6GPQ3, Q6NMN6, Q6NT16, Q6NUB3, Q7ZWG6, Q8AVC3

Diamond homologs: F5H094, G3V0H7, O35913, O88397, O94956, P46720, P46721, P70502, Q00910, Q5RFF0, Q6ZQN7, Q71MB6, Q8BGD4, Q8BXB6, Q8HYW2, Q8R3L5, Q91YY5, Q92959, Q96BD0, Q99J94, Q99N01, Q99N02, Q9EP96, Q9EPT5, Q9EPZ7, Q9ERB5, Q9GMU6, Q9H2Y9, Q9JHI3, Q9JJL3, Q9NPD5, Q9NYB5, Q9QXZ6, Q9QYE2, Q9QZX8, Q9UIG8, Q9Y6L6, Q8K078, Q86UG4, Q8C0X7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

363 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	37
Likely pathogenic	21
Uncertain significance	119
Likely benign	117
Benign	39

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1174120	NM_005630.3(SLCO2A1):c.861+2T>C	Pathogenic
1174121	NM_005630.3(SLCO2A1):c.302T>G (p.Ile101Ser)	Pathogenic
1174123	NM_005630.3(SLCO2A1):c.621C>A (p.Tyr207Ter)	Pathogenic
1174124	NM_005630.3(SLCO2A1):c.1660G>A (p.Gly554Arg)	Pathogenic
1174125	NM_005630.3(SLCO2A1):c.1814+1G>A	Pathogenic
1350810	NM_005630.3(SLCO2A1):c.310G>A (p.Gly104Arg)	Pathogenic
1363789	NM_005630.3(SLCO2A1):c.1264_1265del (p.Thr422fs)	Pathogenic
1483488	NM_005630.3(SLCO2A1):c.1106G>A (p.Gly369Asp)	Pathogenic
1978090	NM_005630.3(SLCO2A1):c.1768del (p.Arg590fs)	Pathogenic
225478	NM_005630.3(SLCO2A1):c.940+1G>A	Pathogenic
2708031	NM_005630.3(SLCO2A1):c.1497dup (p.Ala500fs)	Pathogenic
2920730	NM_005630.3(SLCO2A1):c.421G>T (p.Glu141Ter)	Pathogenic
2920732	NM_005630.3(SLCO2A1):c.1106-1G>A	Pathogenic
2920734	NM_005630.3(SLCO2A1):c.178G>A (p.Glu60Lys)	Pathogenic
2920736	NM_005630.3(SLCO2A1):c.759G>A (p.Trp253Ter)	Pathogenic
2920737	NM_005630.3(SLCO2A1):c.440G>A (p.Trp147Ter)	Pathogenic
2920740	NM_005630.3(SLCO2A1):c.1095C>A (p.Asn365Lys)	Pathogenic
2920742	NM_005630.3(SLCO2A1):c.1668G>C (p.Gln556His)	Pathogenic
2920743	NM_005630.3(SLCO2A1):c.763G>A (p.Gly255Arg)	Pathogenic
2920744	NM_005630.3(SLCO2A1):c.855del (p.Ala286fs)	Pathogenic
2920745	NM_005630.3(SLCO2A1):c.1461+1G>C	Pathogenic
3016178	NM_005630.3(SLCO2A1):c.794del (p.Ser264_Ser265insTer)	Pathogenic
30186	NM_005630.3(SLCO2A1):c.97-1G>A	Pathogenic
30187	NM_005630.3(SLCO2A1):c.764G>A (p.Gly255Glu)	Pathogenic
30188	NM_005630.3(SLCO2A1):c.1634del (p.Asn545fs)	Pathogenic
3068564	NM_005630.3(SLCO2A1):c.209_210insA (p.Leu72fs)	Pathogenic
3688289	NM_005630.3(SLCO2A1):c.1183C>T (p.Gln395Ter)	Pathogenic
3696256	NM_005630.3(SLCO2A1):c.1022del (p.Val341fs)	Pathogenic
37167	NM_005630.3(SLCO2A1):c.830dup (p.Phe278fs)	Pathogenic
37168	NM_005630.3(SLCO2A1):c.754C>T (p.Arg252Ter)	Pathogenic

SpliceAI

2991 predictions. Top by Δscore:

Variant	Effect	Δscore
3:133934829:ACCT:A	acceptor_loss	1.0000
3:133934831:C:CG	acceptor_loss	1.0000
3:133934832:T:C	acceptor_loss	1.0000
3:133935768:CCTCA:C	donor_loss	1.0000
3:133935769:CTCAC:C	donor_loss	1.0000
3:133935770:TCA:T	donor_loss	1.0000
3:133935771:CA:C	donor_loss	1.0000
3:133935773:C:G	donor_loss	1.0000
3:133935773:CCTGT:C	donor_gain	1.0000
3:133938422:CACTT:C	donor_loss	1.0000
3:133938423:ACTT:A	donor_loss	1.0000
3:133938424:CTTA:C	donor_loss	1.0000
3:133938425:TTAC:T	donor_loss	1.0000
3:133938426:TAC:T	donor_loss	1.0000
3:133938427:A:AC	donor_gain	1.0000
3:133938427:AC:A	donor_gain	1.0000
3:133938427:ACCCA:A	donor_loss	1.0000
3:133938428:C:CC	donor_gain	1.0000
3:133938428:CC:C	donor_gain	1.0000
3:133938428:CCCAG:C	donor_gain	1.0000
3:133938489:CCACA:C	acceptor_gain	1.0000
3:133938490:CACA:C	acceptor_gain	1.0000
3:133938490:CACAC:C	acceptor_gain	1.0000
3:133938492:CA:C	acceptor_gain	1.0000
3:133942764:TAGAT:T	acceptor_gain	1.0000
3:133942765:AGAT:A	acceptor_gain	1.0000
3:133942766:GAT:G	acceptor_gain	1.0000
3:133942769:C:CC	acceptor_gain	1.0000
3:133942772:C:CT	acceptor_gain	1.0000
3:133942773:A:T	acceptor_gain	1.0000

AlphaMissense

4178 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:133948597:G:C	F348L	0.999
3:133948597:G:T	F348L	0.999
3:133948599:A:G	F348L	0.999
3:133951300:A:G	W257R	0.998
3:133951300:A:T	W257R	0.998
3:133951297:A:G	W258R	0.997
3:133951297:A:T	W258R	0.997
3:133951310:C:A	W253C	0.997
3:133951310:C:G	W253C	0.997
3:133953734:C:T	G218E	0.997
3:133973755:C:T	G102D	0.997
3:133973793:G:C	S89R	0.997
3:133973793:G:T	S89R	0.997
3:133973795:T:G	S89R	0.997
3:133979526:A:C	F63L	0.997
3:133979526:A:T	F63L	0.997
3:133979528:A:G	F63L	0.997
3:133979530:C:G	R62P	0.997
3:133979535:C:A	E60D	0.997
3:133979535:C:G	E60D	0.997
3:133935839:C:A	W583C	0.996
3:133935839:C:G	W583C	0.996
3:133953722:C:T	G222E	0.996
3:133953735:C:G	G218R	0.996
3:133953735:C:T	G218R	0.996
3:133955043:C:T	G183E	0.996
3:133955050:C:G	G181R	0.996
3:133979490:G:C	S75R	0.996
3:133979490:G:T	S75R	0.996
3:133979492:T:G	S75R	0.996

dbSNP variants (sampled 300 via entrez): RS1000000962 (3:134003481 T>G), RS1000043667 (3:133965163 A>C), RS1000104106 (3:133959916 C>G), RS1000145799 (3:134027586 C>A), RS1000148693 (3:133984310 C>G), RS1000152038 (3:133990933 A>G), RS1000173565 (3:133960052 G>A), RS1000216631 (3:133992857 A>G,T), RS1000221976 (3:133941711 G>A), RS1000277519 (3:134030850 G>A), RS1000283284 (3:133947973 C>T), RS1000368094 (3:133948347 A>T), RS1000432638 (3:134024962 G>C), RS1000468808 (3:133948064 A>G), RS1000520818 (3:133981411 C>T)

Disease associations

OMIM: gene MIM:601460 | disease phenotypes: MIM:167100, MIM:614441, MIM:259100

GenCC curated gene-disease

Disease	Classification	Inheritance
hypertrophic osteoarthropathy, primary, autosomal dominant	Definitive	Autosomal dominant
hypertrophic osteoarthropathy, primary, autosomal recessive, 2	Definitive	Autosomal recessive
inflammatory bowel disease	Strong	Autosomal recessive
pachydermoperiostosis	Supportive	Autosomal recessive
chronic enteropathy associated with SLCO2A1 gene	Supportive	Autosomal recessive

Mondo (6): hypertrophic osteoarthropathy, primary, autosomal dominant (MONDO:0008172), hypertrophic osteoarthropathy, primary, autosomal recessive, 2 (MONDO:0013756), primary hypertrophic osteoarthropathy (MONDO:0016620), (MONDO:0009799), chronic enteropathy associated with SLCO2A1 gene (MONDO:0018766), inflammatory bowel disease (MONDO:0005265)

Orphanet (2): Pachydermoperiostosis (Orphanet:2796), Primary hypertrophic osteoarthropathy (Orphanet:248095)

HPO phenotypes

54 total (30 of 54 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000280	Coarse facial features
HP:0000508	Ptosis
HP:0000771	Gynecomastia
HP:0000845	Elevated circulating growth hormone concentration
HP:0000939	Osteoporosis
HP:0000964	Eczematoid dermatitis
HP:0000969	Edema
HP:0000975	Hyperhidrosis
HP:0000982	Palmoplantar keratoderma
HP:0001051	Seborrheic dermatitis
HP:0001061	Acne
HP:0001072	Thickened skin
HP:0001217	Clubbing
HP:0001231	Abnormal fingernail morphology
HP:0001369	Arthritis
HP:0001376	Limitation of joint mobility
HP:0001386	Joint swelling
HP:0001744	Splenomegaly
HP:0001903	Anemia
HP:0002024	Malabsorption
HP:0002239	Gastrointestinal hemorrhage
HP:0002240	Hepatomegaly
HP:0002650	Scoliosis
HP:0002653	Bone pain
HP:0002754	Osteomyelitis
HP:0002797	Osteolysis
HP:0002829	Arthralgia
HP:0002970	Genu varum

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002337_119	Amyotrophic lateral sclerosis (sporadic)	6.000000e-06
GCST007552_34	Colorectal cancer	2.000000e-12
GCST008839_554	Height	5.000000e-16

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D015212	Inflammatory Bowel Diseases	C06.405.205.731; C06.405.469.432
D010004	Osteoarthropathy, Primary Hypertrophic	C05.116.725; C05.550.648; C16.320.718

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2073703 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 3,118 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL815	DINOPROST	4	3,118

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs34550074	Toxicity	3	Thiazides;plain	Hypertension;Hyponatremia

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs34550074	SLCO2A1	3	2.50	1	Thiazides;plain

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLCO family of organic anion transporting polypeptides

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
bromocresol green	Inhibition	5.44	pKi
bromsulphthalein	Inhibition	5.24	pKi

Binding affinities (BindingDB)

13 measured of 33 human assays (35 total across all organisms); most potent 13 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
NSC_5311503	KI	0.3 nM
NSC_3080928	KI	0.4 nM
CAS_41598-07-6	KI	1.7 nM
PGI2	KI	132 nM
AGN 191995	KI	228 nM
CAS_54751	KI	697 nM
(Z)-7-[(1R,3R,5S)-3,5-Dihydroxy-2-((E)-(S)-3-hydroxy-oct-1-enyl)-cyclopentyl]-hept-5-enoic acid	KI	861 nM
ILOPROST	KI	1040 nM
CAS_94079-80-8	KI	1340 nM
CAS_33458-93-4	KI	1420 nM
PGF2 Alpha, 1-isopropyl ester	KI	3200 nM
U46619	KI	3970 nM
AGN 191366	KI	8130 nM

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.64	Ki	23	nM	DINOPROST
7.42	Ki	38	nM	PROSTAGLANDIN D2
6.83	Ki	149	nM	LATANOPROST ACID

PubChem BioAssay actives

3 with measured affinity, of 18 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Dinoprost	679658: TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells	ki	0.0230	uM
(Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid	679658: TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells	ki	0.0380	uM
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoic acid	679659: TP_TRANSPORTER: inhibition of PGE1 uptake (PGE1: 0.0004 uM) in PGT-expressing HeLa cells	ki	0.1490	uM

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases methylation, affects cotreatment, increases abundance, increases expression, decreases expression	5
Estradiol	increases expression, affects cotreatment, decreases expression, affects binding	4
bisphenol A	increases expression	3
Benzo(a)pyrene	affects methylation, increases expression	3
Aflatoxin B1	decreases methylation, increases expression, increases methylation	3
Arsenic	decreases expression, affects cotreatment, increases abundance	2
Diethylhexyl Phthalate	increases expression, affects cotreatment, affects reaction	2
Progesterone	increases reaction, affects cotreatment, decreases expression, affects expression	2
Tobacco Smoke Pollution	decreases expression	2
Genistein	increases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	increases expression	1
Esketamine	decreases expression	1
bufotalin	decreases expression	1
diethyl phthalate	increases expression, affects cotreatment, affects reaction	1
lead acetate	decreases expression	1
diisononyl phthalate	increases expression, affects cotreatment, affects reaction	1
ethyl-p-hydroxybenzoate	increases expression	1
o,p’-DDT	increases expression	1
sulforaphane	decreases expression	1
perfluorooctanoic acid	increases expression	1
tobacco tar	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
diisobutyl phthalate	increases expression, affects cotreatment, affects reaction	1
butylbenzyl phthalate	affects cotreatment, affects reaction, increases expression	1
cupric chloride	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
lumiracoxib	decreases reaction, increases transport	1
bisphenol S	increases expression	1

ChEMBL screening assays

4 unique, capped per target: 4 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2075322	Functional	TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells	Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities. — Am J Physiol

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4UQ	HuH7-SLCO2A1-KO-c2	Cancer cell line	Male
CVCL_D4UR	HuH7-SLCO2A1-KO-c3	Cancer cell line	Male

Clinical trials (associated diseases)

301 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00167882	PHASE4	COMPLETED	The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels
NCT00205062	PHASE4	TERMINATED	Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)
NCT00567593	PHASE4	COMPLETED	Gene Regulation by Thiazolidinediones
NCT00746395	PHASE4	COMPLETED	Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
NCT01034358	PHASE4	COMPLETED	Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
NCT01056913	PHASE4	COMPLETED	NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
NCT01067547	PHASE4	COMPLETED	A Trial of Iron Replacement in Patients With Iron Deficiency.
NCT01341808	PHASE4	COMPLETED	Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients
NCT01908283	PHASE4	COMPLETED	Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease
NCT01934088	PHASE4	COMPLETED	Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy
NCT02162862	PHASE4	COMPLETED	Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease
NCT02248337	PHASE4	COMPLETED	Low Volume Colon Preparation for IBD
NCT02281799	PHASE4	WITHDRAWN	Thiopurine Induced Pancreatitis in IBD Patients
NCT02392286	PHASE4	TERMINATED	Corticosteroid Dosage for Crohn’s Disease Flare
NCT02437591	PHASE4	COMPLETED	Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
NCT02453776	PHASE4	COMPLETED	Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
NCT02461758	PHASE4	COMPLETED	Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
NCT02566889	PHASE4	TERMINATED	An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
NCT02774057	PHASE4	UNKNOWN	Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD
NCT02806206	PHASE4	UNKNOWN	Prucalopride Prior to Small Bowel Capsule Endoscopy
NCT02946203	PHASE4	COMPLETED	Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients
NCT02994836	PHASE4	COMPLETED	GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )
NCT03220841	PHASE4	UNKNOWN	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study
NCT03351972	PHASE4	COMPLETED	Differences in Preparation for Small Bowel Capsule Endoscopy
NCT03466983	PHASE4	COMPLETED	A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease
NCT03591770	PHASE4	TERMINATED	Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib
NCT03629379	PHASE4	COMPLETED	Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
NCT03723447	PHASE4	COMPLETED	Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
NCT03798691	PHASE4	COMPLETED	Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab
NCT03860012	PHASE4	UNKNOWN	Folic Acid in Pediatric Inflammatory Bowel Disease
NCT03885713	PHASE4	COMPLETED	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
NCT03917303	PHASE4	RECRUITING	Control Crohn Safe Trial
NCT04045782	PHASE4	COMPLETED	Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders
NCT04304950	PHASE4	COMPLETED	Chronotherapy in Inflammatory Bowel Disease
NCT04626947	PHASE4	TERMINATED	Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
NCT04646187	PHASE4	ENROLLING_BY_INVITATION	De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
NCT04835506	PHASE4	ACTIVE_NOT_RECRUITING	Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
NCT04982172	PHASE4	COMPLETED	Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases
NCT05180175	PHASE4	COMPLETED	The Nordic IBD Treatment Strategy Trial
NCT05280405	PHASE4	UNKNOWN	Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study